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Gestational trophoblastic disease (GTD) is a spectrum of pregnancy related disorders ranging 
from pre-malignant hydatidiform mole through to malignant forms collectively referred to as 
gestational trophoblastic neoplasia (GTN). GTN includes the malignant invasive mole, 
choriocarcinoma and rare placental site trophoblastic and epithelioid trophoblastic tumours 
(PSTT/ETT).1 Globally, approximately 18,000 women are diagnosed annually with GTN, most 
of whom are cured with chemotherapy guided by a sensitive disease response biomarker, human 
chorionic gonadotrophin (hCG). However, 0.5-5% of women die from multi-drug resistance, 
necessitating novel approaches. Risk factors for poor survival include drug refractory disease2, 
liver and/or brain metastases3,4 and PSTT/ETT that develops four or more years after the 
antecedent pregnancy.5 
Anti-cancer T-cell activity is regulated by multiple suppressive mechanisms, including tumour-
expressed programmed death ligand 1 (PDL1) signalling to the T-cell inhibitory receptor PD1. 
Monoclonal antibodies to block this pathway, such as the anti-PD1 agent pembrolizumab, have 
shown impressive clinical activity in several cancer types.6  
Placental expression of paternal antigens make this organ a target for maternal immune 
recognition during pregnancy and PDL1 expression maintains gestational tolerance. In pre-
clinical models, loss of placental PDL1/PD1 signalling results in foetal rejection.7 PDL1 is 
strongly expressed by GTN8–10, suggesting its role in tumour immune-evasion. We therefore 
hypothesised that targeting PD-1 inhibitory signalling with pembrolizumab may be effective in 
drug resistant GTN. Here we report the outcomes of four patients treated across two European 
centres. 
Cases 
All patients had genetically verified gestational tumours (Table S1 and supplementary methods) 
with demographics summarised in Table S2. Patient 1 presented aged 39 with choriocarcinoma 
(Figure 1A) and multiple high risk factors including liver and brain metastases. At a second 
relapse three years later, she progressed through a fifth line of treatment including previous high 
dose chemotherapy (Figure 1B). Multiplex immunohistochemistry (IHC) on a chest wall biopsy 
revealed close to 100% tumour PDL1 expression, rich peritumoural and focal densities of tumour 
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infiltrating lymphocytes (TILs; Figure 1C and D) predominantly CD8+ cytotoxic T-cells, half of 
which were PD1+ (Figure 1H). Tumour cells were negative for the class I major 
histocompatibility complex (MHC-I) antigen HLA-A and MHC-II (Figure 1F-G) but positive 
for the immuno-inhibitory, non-classical MHC-I antigen HLA-G (Figure 1E). The serum hCG 
of 80 IU/L normalised to <5 IU/L after four cycles of pembrolizumab (3 mg/kg, every three 
weeks), that was discontinued after five further consolidation cycles. Residual liver lesions 
regressed on serial imaging and she remains in complete remission over 24 months later.  
Patient 2 presented aged 44, 16 years after her last known pregnancy with uterine PSTT/ETT. 
Having failed multiple therapies over seven years (Figure S1A), tumour cells in the original 
hysterectomy sample and a lung metastasis biopsy were >90% PDL1 positive but TILs were 
absent (Figure S1B and C). Tumour cells were negative for HLA-A, pan-MHC-II and HLA-G 
(Figure S2D, E and data not shown). Reimaging after five cycles of pembrolizumab revealed 
disease progression in keeping with a rising serum hCG and she died four months later. 
Patient 3 presented aged 47 with metastatic PSTT to the lung, liver and brain. Her brain 
metastases progressed during third line therapy (Figure S2A). Significant treatment related 
neuropathy precluded further chemotherapy.  IHC on tissue fragments from a uterine biopsy 
revealed > 90% PDL1 staining and the presence of TILs. Tumour cells were negative for HLA-
A and pan-MHC-II but positive for HLA-G. Upon commencing pembrolizumab, the serum hCG 
rose from 73 to 4476 IU/L before falling after four cycles. Re-imaging showed a partial response 
of the pulmonary metastases but multiple new brain lesions (Figure S2B and C). Her serum and 
cerebrospinal fluid hCG normalised after eight cycles. After five consolidation cycles, reimaging 
demonstrated residual uterine necrotic tissue only, confirmed pathologically. She remains in 
remission over 15 months following marker normalisation.  
Patient 4 presented aged 37 with lung metastatic choriocarcinoma. She achieved remission after 
five lines of chemotherapy including high dose. IHC on a lung deposit revealed close to 100% 
tumour PDL1 expression with dense peri- and intratumoural foci of TILs, composed of 
approximately equal numbers of predominantly PD1 negative CD8+ and CD4+ helper T-cells 
with a high density of CD56+ natural killer (NK) cells. Tumour cells were HLA-A/MHC-II 
negative and HLA-G positive (Figure S1B-F and data not shown). On relapse five months later 
with lung and pelvic nodal disease, her hCG was 118 IU/L and pembrolizumab was commenced 
with marker normalisation after two cycles (Figure S3A). She received five consolidation 
courses and remains in remission over 5 months later.  
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Treatment was well tolerated in all cases with mild (grade 1-2) toxicities managed conservatively 
and details presented in Table S1. 
Discussion 
Patients with unresectable drug resistant GTN have a fatal outcome and anti-PD1 
immunotherapy may be a life-saving treatment. The efficacy and favourable toxicity profile of 
pembrolizumab make its earlier use an attractive alternative to high dose chemotherapy. 
However, lasting fertility impairment due to persistent anti-trophoblast immunity is a concern 
that requires further study before offering therapy earlier in the treatment sequence.  
As previously reported, we found GTN to strongly express PD-L1 that in this small sample was 
not a biomarker of response to immunotherapy. Features of the TIL landscape correlate with 
anti-PD1 response,11 suggesting a causal link between TIL absence and outcome in the single 
non-responder.  
Several cell types may mediate the effect of pembrolizumab on GTN rejection. Trophoblasts do 
not express the classical MHC-I molecules HLA-A/B, nor MHC–II, offering protection from T-
cell mediated placental destruction.12 We report that GTN is similarly negative for HLA-A and 
MHC-II. The strong presence of infiltrating T-cells in responders suggests pembrolizumab 
activation of HLA-C directed or indirect T-cell cytotoxicity. Effectors other than classically 
restricted T-cells may also be relevant. One candidate are NK cells that express PD-1, are 
cytotoxic towards classical MHC-I negative cells and are inhibited by HLA-G, that also acts to 
maintain gestational tolerance through mechanisms including T-cell suppression.13 Upregulated 
tumour expression of HLA-G by the responders suggests a role for this molecule in inhibiting 
infiltrating lymphocyte effectors. Beyond T-cell activation, the immune effects of 
pembrolizumab are not well understood but potentially of wider relevance, especially as HLA-
G expression is a recognised mediator of tumour immune evasion.14 
Complex restrictions precluded public funding of potentially life-saving off-label 
pembrolizumab for the UK treated patients 1-3. This report emphasizes the need to improve 
mechanisms for funding rare disease treatments, for which randomised trials and established 
licencing pathways are not feasible. Based on the evidence presented here, UK public funding 
of pembrolizumab for drug resistant GTN is now under review. 
In summary, we provide evidence in favour of pembrolizumab as an important advance in the 
management of drug resistant GTN that should strongly be considered in this setting. Tumour 
infiltrating lymphocytes and HLA-G expression may identify responders and our analysis of 
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MHC expression suggests potential effects of pembrolizumab on cell types other than classically 
restricted T-cells.  
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Figure 1. (A) Partial electropherograms of DNA from patient 1, her partner and tumour tissue. Genotyping of 
the tumour for short tandem repeat loci D21S11, D7S820 (shown) demonstrates a single non-maternal allele 
(solid peak) representing a contribution to the tumour genome from the partner. Both maternal alleles (open 
peaks) are present in the tumour DNA, the lower open peak (left) representing contamination from maternal 
cells in the tumour sections, while the higher open peak (right) represents a maternal contribution to the tumour 
genome plus a small proportion of contamination from maternal cells in the tumour sections. (B) Serum hCG 
is plotted against time from treatment initiation. Shaded bands represent duration of chemo- and 
immunotherapy with; a. Low dose EP; b. EP/EMA with IT MTX; c. TE/TP; d. HDCT; e. EP; f. Gem-TIP; 
Pembro, pembrolizumab (arrowheads show treatment dates). See Table S2 for a summary of therapeutic 
regimens. (C-F) Multiplex immunohistochemistry of the tumour immune landscape. (C)  Expression of PDL1 
and tumour infiltrating lymphocyte (TIL) expression of the activation/exhaustion marker PD1 and CD56 
expressing natural killer cells; (D) TIL expression of CD4, PD1, FOXP3 (regulatory T-cells that co-express 
CD4) and CD8; (E-G) tumour expression of HLA-G,  HLA-A and MHC-II. The latter three markers were 
counterstained for PDL1 expression to identify tumour cells. Normal HLA-A/MHC-II expression is seen on 
non-cancer cells including endothelial cells and lymphocytes, bars represent 50 µm. (H) TILs in three areas 
comprising one third of the tumour were digitally and manually counted and the mean proportions normalised 






Materials and methods 
Multiplex immunohistochemistry 
Tumour samples and reactive human tonsil tissue were fixed in 10% buffered formalin and 
embedded in paraffin according to standard protocols. 2-5m tissue sections were cut and 
transferred onto poly-l-lysine–coated slides, dewaxed in two changes of xylene and rehydrated 
in a series of graded alcohols. Single immunohistochemistry was carried out using the automated 
platforms BenchMark Ultra (Ventana/Roche) and the Bond-III Autostainer (Leica 
Microsystems) according to a protocol described elsewhere.1,2 To establish optimal staining 
conditions each antibody was tested and optimized on sections of human reactive tonsil, used as 
positive control. Monoclonal antibodies used were as follows; anti-CD4 (Spring Biosciences, 
clone SP35), anti-CD8 (Spring Biosciences, clone SP239), anti-PD1 clone NAT 105/E3 and anti-
FOXP3 clone 236/E7 (kindly gifted by Dr. G. Roncador), anti-CD56 clone CD564 (Leica 
Microsystems), anti-HLA-A clone EP1395Y, anti-HLA-G clone 4H84 and anti-pan-MHC-II 
clone CR3/43 (Abcam). Anti-PDL1 clone SP263 (Ventana) was used to score tumour PDL1 
status, whereas anti-PDL1 clone QR1 (Quarttet) was used to identify tumour cells in dual 
staining with anti-MHC antibodies. 
Multiplex immunohistochemistry was carried out using a protocol described previously.3  
Specificity of the staining was assessed by a haematopathologist (TM) with expertise in 
multiplex-immunostaining. Slides were scanned using the Hamamatsu Nanozoomer Digital 
scanner. Staining was independently reviewed by a second pathologist with expertise in GTD 
(BK). Cell counts for Patient 1 were determined in ImageJ using automatic and manual methods. 
Fluorescent microsatellite genotyping of tumour tissue. 
In each case tumour and surrounding host tissue were independently microdissected from 
formalin-fixed, paraffin-embedded (FFPE) pathological sections of tumour tissue, with reference 
to a haematoxylin and eosin stained section. DNA was prepared from tumour and host tissue in 
all cases using a QIAmp DNA FFPE Tissue Kit (Qiagen; cases 1-3) or a PicoPure DNA 
extraction kit (Arcturus; case 4) and from blood samples from the patient and her partner in case 
1 and 3. DNA was amplified with primers for 15 short tandem repeat (STR) loci on 13 
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chromosomes, together with the amelogenin locus, using an AmpFlSTR Identifiler Plus kit 
(Applied Biosystems; cases 1-3) or 9 STR using an AmpFlSTR Profiler Plus. Kit (Applied 
Biosystems; case 4). PCR products were resolved by capillary electrophoresis using an ABI 3100 
or 3500 Genetic Analyser and genotypes determined using GeneMapper version 5.0 (Applied 
Biosystems) or GeneMarker version 2.4 software (SoftGenetics LLC). Demonstration of the 
presence of paternal alleles, or non-maternal alleles in cases 2 and 4 in DNA from the tumour 
confirmed a diagnosis of gestational trophoblastic neoplasia. 
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Numbers represent alleles identified for informative tandem repeat loci and the amelogenin locus. Genotypes at the TPOX locus were uninformative in all cases. All tumours had a single sex 
chromosome specific peak representing DNA from the X chromosome.  * Loci for which loss of heterozygosity was observed in cases 1 and 3; N/S, not scored. N/D, not done. DNA was not 
available for the partner of Patients 2 and 4.
Table S1. Genotyping of patient, tumour and partner tissue confirms gestational origin of the tumour 
               
Locus: D8S1179 D21S11 D7S820 CSF1PO D3S1358 THO1 D13S317 D16S539 D2S1338 D19S433 vWA D18S51 D5S818 FGA 
Patient 1               
Patient 11 29 - 30 11 - 12 9 - 14 14 - 18 8 - 9  9 - 11 9 - 11 18 - 20 14.2 - 16 17 - 18 15 - 17 10 - 11 19 - 22 
Tumour 11 27 - 30 8 - 12 9 - 10 18 6* 9 - 13 10 - 11 20 14.2-15.2 17 - 18 15 - 18 10 - 13 26* 
Partner 10 - 11 27 - 29 8 - 10 10 14 - 18 6 - 8 13 8 - 10 19 - 20 14.2-15.2 17 - 18 18 11 - 13 20 - 26 
Patient 2               
Patient 10 - 13 30 - 31 9 - 11 12 15 - 18 6 - 7 11 - 16 9 - 10 17 - 20 14 14 - 17  12 - 17  11 - 12 18 - 22 
Tumour 10 - 15 31 - 31.2 9 - 10 12 15 - 17 6 - 9 10 - 16 9 - 11 17 14 - 16.2 17  16  - 17 11 18 - 20 
Patient 3               
Patient 12 31 - 32.2  11 10 - 11 15 9 11 - 16 9 20 - 21 13 - 15 14 14 - 15  11 23 - 24 
Tumour 12* 30 - 31 8 - 11 N/S 15 - 17 9 11 - 16 9 - 12  21 - 25 N/S 14 - 16 14 - 15  11 19 - 24 
Partner 10 - 15 30 8 - 10 11 - 12 17 9 - 9.3 11 - 16 11 - 12  22 - 25 13 16 - 17 15 - 20 10 - 11  19 
Patient 4               
Patient 12 N/S 8 - 9 N/D 16 - 18 N/D 9 - 11 N/D N/D N/D 17 - 20 18 - 18.2 10 - 11 22 - 25 





1Age or performance status at commencement of pembrolizumab. TM, thoracic metastasectomy; HBSO, hysterectomy and bilateral salpingo-oophorectomy; G (gravida); P (para). CR, complete 
response; PD, progressive disease; PR, partial response. Adverse events were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.03. Radiological responses 
were evaluated according to Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. Details of chemotherapeutic regimens are given in Table S3.
Table S2.  Summary of patient baseline characteristics and prior therapies. 
     
 Patient 1 Patient 2 Patient 3 Patient 4 
Age1 42 52 48 37 
Performance status1 0 2 1 0 
Obstetric status G2P2 G3P3 G3P2 G2P2 
GTN subtype CC ETT (predominant)/PSTT PSTT CC 
Antecedent pregnancy (years) 3 16 11 0.75 
Sites of disease 
Nodal, hepatic 
Nodal, hepatic, pulmonary, 
pleural 
Pelvic, hepatic, pulmonary, 
brain 
Nodal, hepatic 
Disease duration (years) 2.6 7.8 0.6 1.25 
FIGO score at diagnosis 17 8 20 6 
Prior chemotherapy (cycles)     
1 Induction EP (1) EP/EMA (8) Induction EP (3) IM MTX (2) 
2 
EP/EMA CNS (8), IT MTX (2) TE/TP (4) EP/EMA CNS (5), IT MTX (3) 
EMA/CO (8) 
IT MTX (3) 
3 
TE/TP (4) - 
TE/TP (4) 
IT MTX (3) 
TE/TP (2) 
EP/EMA (1) 
4 HDCT (2) - Escalated EP (5), IT MTX (8) HDCT (2) 
5 Escalated EP (6) - - - 
6 Gem-TIP (2) - - - 
Prior surgery TM HBSO,  TM - TM 
Serum hCG 80 2468 73 118 
Biochemical response and duration 
(months) 
CR (24) PD CR (15) CR (5) 
Radiological response Ongoing PR PD Ongoing PR Ongoing PR 
Pembrolizumab     
Cycles to hCG normalisation 4 - 8 2 
Consolidation cycles 5 - 5 5 





























IM, intramuscular; IT, intrathecal; D, day; AUC, area under the concentration-time curve. a. Patient 4 received 
pembrolizumab 200 mg every 2 weeks. b, For Patient 1, carboplatin AUC 4 was substituted for cisplatin. Patient 





Table S3. Treatment regimens 
  
Regimen and cycle 
length (weeks) 
Agent and dose 
Pembrolizumaba (3) 3 mg/kg pembrolizumab D1 
  
IM MTX (2) 50 mg methotrexate D1, 3, 5, 7 
  
EMA/CO (2)  
EMA 0.5 mg actinomycin D1, 2 
 100 mg/m2 etoposide D1, 2 
 300 mg/m2 methotrexate D1 
  
CO 1 g/m2 vincristine D8 
 600 mg/m2 cyclophosphamide D8 
  
Induction EP (1) 100 mg/m2 etoposide D1, 2 
 20 mg/m2 cisplatin D1, 2 
EP/EMA CNSb (2)  
EMA 0.5 mg actinomycin D1, 2 
 100 mg/m2 etoposide D1, 2 
 1000 mg/m2 methotrexate D1 
  
EP 150 mg/m2 etoposide D8 
 75 mg/m2 cisplatin D8 
  
IT MTX (2) 12.5 mg methotrexate D1 
  
TE/TPc (4)  
TE 150 mg/m2 etoposide D1 
 135 mg/m2 paclitaxel D1 
  
TP 60 mg/m2 cisplatin D14 
 135 mg/m2 paclitaxel D14 
  
Escalated EP (2) 500mg/m2 etoposide D1 
 60mg/m2 cisplatin D1 
  
Gem-TIP (3) 1200 mg/m2 gemcitabine D1 
 175 mg/m2 paclitaxel D1 
 1000 mg/m2 ifosfamide D2-6 
 20 mg/m2 cisplatin D2-6 
  
HDCT 75  mg/m2 paclitaxel D-7, -5, -3 
 450  mg/m2 etoposide D-7, -5, -3 
 AUC 10 carboplatin D-7, -5, -3 
 60  mg/kg cyclophosphamide D-5, -3 
 Autologous haematopoietic stem cells D0 
14 
 



























 (A) Serum hCG is plotted against time from treatment initiation. Shaded bands represent duration of chemo- and 
immunotherapy with; a. EP/EMA; Pembro, pembrolizumab (arrowheads show treatment dates). H, hysterectomy; t, thoracic 
metastasectomy. TE/TP was additionally given prior to pembrolizumab at another institution (data not shown), see Table 
S2 for a summary of therapeutic regimens. (B-E) Multiplex immunohistochemistry on the uterine primary showing staining 
for PDL1, PD1 and CD56 (B); CD4, PD1, FOXP3 and CD8 (C); HLA-G (D) and HLA-A (F). The latter two were 
counterstained for PDL1 expression to identify tumour cells. Normal HLA-A expression is seen on non-cancer cells 














 (A) Serum hCG is plotted against time from treatment initiation. Shaded bands represent duration of chemo- and 
immunotherapy with; a. Induction EP; b. EP/EMA CNS; c. TE/TP; d. Escalated EP; Pembro, pembrolizumab (arrowheads 
show treatment dates). For treatments b-d, IT MTX was given concurrently. See Table S2 for a summary of therapeutic 
regimens. Serum (blue) and cerebrospinal fluid (CSF; purple) hCG response is shown. (B-C) Radiological response to 
pembrolizumab. (B) Serial contrast enhanced MRI head scans show flare and resolution of a brain metastasis. (C) Serial 
CT chest imaging shows resolution of a lung metastasis. Numbers represent months following initiation of pembrolizumab 





Figure S3. Treatments, response and immunophenotyping for Patient 4 
 
(A) Serum hCG is plotted against time from treatment initiation. Shaded bands represent duration of chemo- 
and immunotherapy with; a. IM MTX; b. EMA/CO and IT MTX; c. TE/TP (and a single cycle of EP/EMA); 
d. HDCT; Pembro, pembrolizumab (arrowheads show treatment dates). t, thoracic metastasectomy. See Table 
S2 for a summary of therapeutic regimens. (B) Tumour infiltrating lymphocytes (TILs) in three areas 
comprising one third of the tumour were manually counted and the mean proportions normalised to CD8 T-
cells. Error bars represent standard deviation. (C-F) Multiplex immunohistochemistry showing expression of 
PDL1, the activation/exhaustion marker PD1 and CD56 expressing natural killer cells (C); phenotype of TILs 
stained for CD4, PD1, FOXP3 (regulatory T-cells that co-express CD4) and CD8 (D); tumour HLA-G (E) and 
HLA-A (F). The latter two were counterstained for PDL1 expression to identify tumour cells. Normal HLA-
A expression is seen on non-cancer cells predominantly representing stromal and inflammatory cells, bars 
represent 50 µm. 
